Mathai Mammen Biography and Net Worth

Mathai Mammen, M.D., Ph.D. has served on our board of directors since August 2017. Dr. Mammen currently serves as global head, research and development at the Janssen Pharmaceutical Companies of Johnson & Johnson. Prior to joining Janssen Pharmaceutical Companies in June 2017, Dr. Mammen was Senior Vice President at Merck Research Laboratories from March 2016 to June 2017. Prior to Merck, Dr. Mammen led research and development at Theravance, a company he co-founded in 1997 until March 2016. In 2014, he and the Theravance Leadership Team separated Theravance into two publicly traded companies: Innoviva and Theravance Biopharma. Dr. Mammen received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University’s Department of Chemistry. He received his B.Sc. in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.

What is Mathai Mammen's net worth?: The estimated net worth of Mathai Mammen is at least $4.68 million as of May 11th, 2023. Dr. Mammen owns 169,745 shares of 10x Genomics stock worth more than $4,683,265 as of April 27th. This net worth estimate does not reflect any other assets that Dr. Mammen may own. Learn More about Mathai Mammen's net worth.
How do I contact Mathai Mammen?: The corporate mailing address for Dr. Mammen and other 10x Genomics executives is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. 10x Genomics can also be reached via phone at 925-401-7300 and via email at [email protected]. Learn More on Mathai Mammen's contact information.
Has Mathai Mammen been buying or selling shares of 10x Genomics?: Mathai Mammen has not been actively trading shares of 10x Genomics during the last ninety days. Most recently, Mathai Mammen sold 33,000 shares of the business's stock in a transaction on Thursday, May 11th. The shares were sold at an average price of $52.82, for a transaction totalling $1,743,060.00. Following the completion of the sale, the director now directly owns 169,745 shares of the company's stock, valued at $8,965,930.90. Learn More on Mathai Mammen's trading history.
Who are 10x Genomics' active insiders?: 10x Genomics' insider roster includes Bradford Crutchfield (Insider), Benjamin Hindson (Insider), Sridhar Kosaraju (Director), Mathai Mammen (Director), Justin McAnear (CFO), Serge Saxonov (CEO), John Stuelpnagel (Director), and James Wilbur (Insider). Learn More on 10x Genomics' active insiders.
Are insiders buying or selling shares of 10x Genomics?: During the last year, insiders at the sold shares 29 times. They sold a total of 182,020 shares worth more than $9,613,552.06. The most recent insider tranaction occured on March, 4th when CEO Serge Saxonov sold 4,660 shares worth more than $205,040.00. Insiders at 10x Genomics own 10.7% of the company. Learn More about insider trades at 10x Genomics.
Information on this page was last updated on 3/4/2024.

Mathai Mammen Insider Trading History at 10x Genomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/11/2023	Sell	33,000	$52.82	$1,743,060.00	169,745

Mathai Mammen Buying and Selling Activity at 10x Genomics

10x Genomics Company Overview

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Today's Range

Now: $27.59

$26.60

$27.94

50 Day Range

MA: $37.70

$26.90

$48.45

2 Week Range

Now: $27.59

$26.30

$63.57

Volume

1,337,623 shs

Average Volume

1,534,682 shs

Market Capitalization

$3.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy